Pediatrix Medical Group (NYSE:MD) Lowered to "Hold" Rating by StockNews.com

Pediatrix Medical Group (NYSE:MD - Get Free Report) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Thursday.

Several other equities analysts also recently commented on the company. Deutsche Bank Aktiengesellschaft upped their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research note on Monday, November 4th. UBS Group upped their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Mizuho increased their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a research report on Tuesday. Finally, Jefferies Financial Group increased their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $16.10.

Pediatrix Medical Group Stock Performance

MD stock opened at $14.49 on Thursday. The firm has a market cap of $1.24 billion, a PE ratio of -4.74, a P/E/G ratio of 2.03 and a beta of 1.55. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The business has a 50 day moving average of $12.77 and a 200-day moving average of $9.96. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $16.41.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same quarter in the prior year, the business earned $0.29 earnings per share. Pediatrix Medical Group's revenue for the quarter was up .9% on a year-over-year basis. As a group, sell-side analysts expect that Pediatrix Medical Group will post 1.25 earnings per share for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company's stock, valued at $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the transaction, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. This represents a 18.52 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,808 shares of company stock valued at $751,277. 2.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Pediatrix Medical Group by 1.6% during the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company's stock valued at $105,892,000 after buying an additional 164,333 shares during the last quarter. Rubric Capital Management LP boosted its holdings in shares of Pediatrix Medical Group by 1.5% during the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company's stock worth $95,907,000 after purchasing an additional 125,000 shares during the period. State Street Corp boosted its holdings in shares of Pediatrix Medical Group by 1.4% during the third quarter. State Street Corp now owns 3,540,791 shares of the company's stock worth $41,038,000 after purchasing an additional 50,597 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Pediatrix Medical Group by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company's stock worth $22,452,000 after purchasing an additional 45,155 shares during the period. Finally, Boston Partners boosted its holdings in shares of Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company's stock worth $17,702,000 after purchasing an additional 453,254 shares during the period. 97.71% of the stock is owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.